496 related articles for article (PubMed ID: 37569510)
1. α-Synuclein Strains and Their Relevance to Parkinson's Disease, Multiple System Atrophy, and Dementia with Lewy Bodies.
Graves NJ; Gambin Y; Sierecki E
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569510
[TBL] [Abstract][Full Text] [Related]
2. The structural differences between patient-derived α-synuclein strains dictate characteristics of Parkinson's disease, multiple system atrophy and dementia with Lewy bodies.
Van der Perren A; Gelders G; Fenyi A; Bousset L; Brito F; Peelaerts W; Van den Haute C; Gentleman S; Melki R; Baekelandt V
Acta Neuropathol; 2020 Jun; 139(6):977-1000. PubMed ID: 32356200
[TBL] [Abstract][Full Text] [Related]
3. Disease-, region- and cell type specific diversity of α-synuclein carboxy terminal truncations in synucleinopathies.
Hass EW; Sorrentino ZA; Xia Y; Lloyd GM; Trojanowski JQ; Prokop S; Giasson BI
Acta Neuropathol Commun; 2021 Aug; 9(1):146. PubMed ID: 34454615
[TBL] [Abstract][Full Text] [Related]
4. Neuropathology and molecular diagnosis of Synucleinopathies.
Koga S; Sekiya H; Kondru N; Ross OA; Dickson DW
Mol Neurodegener; 2021 Dec; 16(1):83. PubMed ID: 34922583
[TBL] [Abstract][Full Text] [Related]
5. RT-QuIC Using C-Terminally Truncated α-Synuclein Forms Detects Differences in Seeding Propensity of Different Brain Regions from Synucleinopathies.
Poggiolini I; Erskine D; Vaikath NN; Ponraj J; Mansour S; Morris CM; El-Agnaf OMA
Biomolecules; 2021 May; 11(6):. PubMed ID: 34072869
[TBL] [Abstract][Full Text] [Related]
6. Is Multiple System Atrophy a Prion-like Disorder?
Jellinger KA; Wenning GK; Stefanova N
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576255
[TBL] [Abstract][Full Text] [Related]
7. ɑ-Synuclein strains and seeding in Parkinson's disease, incidental Lewy body disease, dementia with Lewy bodies and multiple system atrophy: similarities and differences.
Peelaerts W; Bousset L; Baekelandt V; Melki R
Cell Tissue Res; 2018 Jul; 373(1):195-212. PubMed ID: 29704213
[TBL] [Abstract][Full Text] [Related]
8. 14-3-3 Proteins Reduce Cell-to-Cell Transfer and Propagation of Pathogenic α-Synuclein.
Wang B; Underwood R; Kamath A; Britain C; McFerrin MB; McLean PJ; Volpicelli-Daley LA; Whitaker RH; Placzek WJ; Becker K; Ma J; Yacoubian TA
J Neurosci; 2018 Sep; 38(38):8211-8232. PubMed ID: 30093536
[TBL] [Abstract][Full Text] [Related]
9. α-Synuclein conformers reveal link to clinical heterogeneity of α-synucleinopathies.
Schmitz M; Candelise N; Canaslan S; Altmeppen HC; Matschke J; Glatzel M; Younas N; Zafar S; Hermann P; Zerr I
Transl Neurodegener; 2023 Mar; 12(1):12. PubMed ID: 36915212
[TBL] [Abstract][Full Text] [Related]
10. [Role of fatty acid-binding protein 7 and novel therapeutic approach in synucleinopathies].
Cheng A; Fukunaga K
Nihon Yakurigaku Zasshi; 2022; 157(6):396-400. PubMed ID: 36328545
[TBL] [Abstract][Full Text] [Related]
11. RT-QuIC and Related Assays for Detecting and Quantifying Prion-like Pathological Seeds of α-Synuclein.
Srivastava A; Alam P; Caughey B
Biomolecules; 2022 Apr; 12(4):. PubMed ID: 35454165
[TBL] [Abstract][Full Text] [Related]
12. Alpha-Synuclein Oligomers and Neurofilament Light Chain in Spinal Fluid Differentiate Multiple System Atrophy from Lewy Body Synucleinopathies.
Singer W; Schmeichel AM; Shahnawaz M; Schmelzer JD; Boeve BF; Sletten DM; Gehrking TL; Gehrking JA; Olson AD; Savica R; Suarez MD; Soto C; Low PA
Ann Neurol; 2020 Sep; 88(3):503-512. PubMed ID: 32557811
[TBL] [Abstract][Full Text] [Related]
13. α-Synuclein Radiotracer Development and In Vivo Imaging: Recent Advancements and New Perspectives.
Alzghool OM; van Dongen G; van de Giessen E; Schoonmade L; Beaino W
Mov Disord; 2022 May; 37(5):936-948. PubMed ID: 35289424
[TBL] [Abstract][Full Text] [Related]
14. Different α-synuclein prion strains cause dementia with Lewy bodies and multiple system atrophy.
Ayers JI; Lee J; Monteiro O; Woerman AL; Lazar AA; Condello C; Paras NA; Prusiner SB
Proc Natl Acad Sci U S A; 2022 Feb; 119(6):. PubMed ID: 35115402
[TBL] [Abstract][Full Text] [Related]
15. Unique α-synuclein pathology within the amygdala in Lewy body dementia: implications for disease initiation and progression.
Sorrentino ZA; Goodwin MS; Riffe CJ; Dhillon JS; Xia Y; Gorion KM; Vijayaraghavan N; McFarland KN; Golbe LI; Yachnis AT; Giasson BI
Acta Neuropathol Commun; 2019 Sep; 7(1):142. PubMed ID: 31477175
[TBL] [Abstract][Full Text] [Related]
16. Lipids as
Ikenaka K; Suzuki M; Mochizuki H; Nagai Y
Front Neurosci; 2019; 13():693. PubMed ID: 31333408
[TBL] [Abstract][Full Text] [Related]
17. New insights into cellular α-synuclein homeostasis in health and disease.
Dettmer U; Selkoe D; Bartels T
Curr Opin Neurobiol; 2016 Feb; 36():15-22. PubMed ID: 26282834
[TBL] [Abstract][Full Text] [Related]
18. α-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies.
Wong YC; Krainc D
Nat Med; 2017 Feb; 23(2):1-13. PubMed ID: 28170377
[TBL] [Abstract][Full Text] [Related]
19. Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy.
Nimmo JT; Verma A; Dodart JC; Wang CY; Savistchenko J; Melki R; Carare RO; Nicoll JAR
Alzheimers Res Ther; 2020 Nov; 12(1):159. PubMed ID: 33256825
[TBL] [Abstract][Full Text] [Related]
20. ɑ-Synuclein strains and the variable pathologies of synucleinopathies.
Peelaerts W; Baekelandt V
J Neurochem; 2016 Oct; 139 Suppl 1():256-274. PubMed ID: 26924014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
